Discovery Genomics, Inc. (DGI) was founded in 2000 and became operational in January 2002. DGI maintains exclusive rights to two breakthrough technologies that significantly enhance the development of new therapeutics - from gene discovery to treatment delivery.
Our primary focus is to use these proprietary technologies to deliver gene therapies for blood diseases in collaboration with strategic partners. To advance our gene therapy development efforts, we also seek to license our technologies in areas outside our therapeutic focus.
